Sanofi and GSK, which co-developed this vaccine, will seek regulatory approval for their product in the United States and the European Union.
Article written by
Published
Update
Reading time : 1 min.
The French pharmaceutical giant Sanofi announced, on Wednesday February 23, large-scale positive results for its vaccine against Covid-19, developed with the British GSK. The two groups will therefore “seek regulatory approval for their vaccine” in the United States and the European Union.
The groups assure in a press release that their vaccine is effective at “100% against severe forms (…) and hospitalizations”at “75% against moderate to severe forms” and to “57.9% against all symptomatic forms”. A result “comparable to the effectiveness of vaccines already available”they conclude.
Sanofi had initially abandoned the development of a vaccine against Covid-19 with messenger RNA, before announcing in December a new delay for its other product using a more traditional technology.